Data releases from GenOMICC

Release 1 (September 2020): 2,244 critical Covid cases

Discovery and replication of four new associations with critical Covid-19: OAS1, DPP9, TYK2 and IFNAR2, taking the total number of robust associations with critical Covid-19 to 5. Medrxiv. September 2020; Nature. December 2020.

Bulk Summary Statistics Downloads:

Full summary statistics for each genetic ancestry group are available here (see manuscript for details):

GenoMICC r1 EUR vs UK biobank (84.1Mb)
GenoMICC r1 AFR vs UK biobank (60.5Mb)
GenoMICC r1 EAS vs UK biobank (52.5Mb)
GenoMICC r1 SAS vs UK biobank (62.4Mb)

Release 2 (August 2021): 7,491 critical Covid cases

Discovery and replication of fifteen new associations with critical Covid-19, including BCL11A, PLSCR1, MUC1, ACSL6/CSF2, IFNA10, ELF5, FBRSL1, ATP11A, FUT2, and IL10RB, taking the total number of robust associations with critical Covid-19 to 24. Medrxiv. August 2021, Nature. March 2022.

Bulk Summary Statistics Downloads:

GenOMICC_r2_AFR.txt.gz (470.0Mb)
GenOMICC_r2_EAS.txt.gz (197.3Mb)
GenOMICC_r2_EUR.txt.gz (298.9Mb)
GenOMICC_r2_SAS.txt.gz (298.9Mb)
GenOMICC_r2_metaanalysis.txt.gz (151.)
metatwas.csv (3.781Mb)
twas_Lung.csv (810.0Kb)
twas_Whole_Blood.csv (677.6Kb)
license_text (17.00Kb)

Release 3 (March 8th 2022): 11,000 critical Covid cases

These are unpublished results, under embargo until publication of the full report

In release 3 we add an additional 5836 cases from the GenOMICC Study and ISARIC4C (13327 cases in total), and combine with unpublished data from collaborators in SCOURGE (5934 cases) and 23andMe (1410 cases) and published data from the HGIv6 meta-analysis. We find an additional 14 new genetic associations including potentially druggable targets in inflammatory signalling (JAK1, PDE4A), monocyte-macrophage differentiation (CSF2), immunometabolism (SLC2A5, AK5), and host factors required for viral entry and replication (TMPRSS2, RAB2A). MedRxiv March 8th 2022

These latest unpublished results for this data release are shared with the global community before publication in order to accelerate discovery. We share our results on the understanding that no investigator should publish any work derived from these results without express aggreement of the GenOMICC Investigators.